Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14284041 | 0.71 | DRD2 (0.44) | OPRD1OPRK1OPRM1 | |
| Hydrochloric Acid SCHEMBL7291688 | 0.67 | OPRK1 (0.44) | OPRD1OPRK1OPRM1 | |
| Hydrochloric Acid SCHEMBL7291696 | 0.67 | OPRK1 (0.44) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4975869 | 0.66 | OPRD1 (0.33) | OPRD1OPRK1OPRM1 | |
| SCHEMBL29761185 | 0.65 | CXCR3 (0.44) | OPRK1OPRM1 | |
| SCHEMBL1696871 | 0.61 | NCF1 (0.39) | — | |
| SCHEMBL6045459 | 0.61 | NPFFR1 (0.45) | OPRD1OPRK1OPRM1EGLN1 | |
| SCHEMBL694189 | 0.60 | CHRM2 (0.62) | OPRD1OPRK1OPRM1 | |
| SCHEMBL13993541 | 0.60 | CHRM2 (0.62) | OPRD1OPRK1OPRM1 | |
| SCHEMBL16766562 | 0.60 | CHRM2 (0.62) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | OPRD1 30/4885OPRK1 51/4885OPRM1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.